225 related articles for article (PubMed ID: 30944027)
1. The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1.
Cairns J; Ingle JN; Kalari KR; Shepherd LE; Kubo M; Goetz MP; Weinshilboum RM; Wang L
Breast Cancer Res; 2019 Apr; 21(1):47. PubMed ID: 30944027
[TBL] [Abstract][Full Text] [Related]
2. Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy.
Ingle JN; Xie F; Ellis MJ; Goss PE; Shepherd LE; Chapman JW; Chen BE; Kubo M; Furukawa Y; Momozawa Y; Stearns V; Pritchard KI; Barman P; Carlson EE; Goetz MP; Weinshilboum RM; Kalari KR; Wang L
Cancer Res; 2016 Dec; 76(23):7012-7023. PubMed ID: 27758888
[TBL] [Abstract][Full Text] [Related]
3. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer.
Giamas G; Filipović A; Jacob J; Messier W; Zhang H; Yang D; Zhang W; Shifa BA; Photiou A; Tralau-Stewart C; Castellano L; Green AR; Coombes RC; Ellis IO; Ali S; Lenz HJ; Stebbing J
Nat Med; 2011 Jun; 17(6):715-9. PubMed ID: 21602804
[TBL] [Abstract][Full Text] [Related]
4. High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.
Asano T; Sato S; Yoshimoto N; Endo Y; Hato Y; Dong Y; Takahashi S; Fujii Y; Toyama T
Jpn J Clin Oncol; 2014 Oct; 44(10):889-97. PubMed ID: 25163465
[TBL] [Abstract][Full Text] [Related]
5. SGK3 sustains ERα signaling and drives acquired aromatase inhibitor resistance through maintaining endoplasmic reticulum homeostasis.
Wang Y; Zhou D; Phung S; Warden C; Rashid R; Chan N; Chen S
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):E1500-E1508. PubMed ID: 28174265
[TBL] [Abstract][Full Text] [Related]
6. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway.
Barone I; Cui Y; Herynk MH; Corona-Rodriguez A; Giordano C; Selever J; Beyer A; Andò S; Fuqua SA
Cancer Res; 2009 Jun; 69(11):4724-32. PubMed ID: 19487288
[TBL] [Abstract][Full Text] [Related]
7. LMTK3 confers chemo-resistance in breast cancer.
Stebbing J; Shah K; Lit LC; Gagliano T; Ditsiou A; Wang T; Wendler F; Simon T; Szabó KS; O'Hanlon T; Dean M; Roslani AC; Cheah SH; Lee SC; Giamas G
Oncogene; 2018 Jun; 37(23):3113-3130. PubMed ID: 29540829
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a suppresses cell proliferation by targeting LMTK3 in human breast cancer mcf-7 cell line.
Zhao G; Guo J; Li D; Jia C; Yin W; Sun R; Lv Z; Cong X
DNA Cell Biol; 2013 Dec; 32(12):699-707. PubMed ID: 24050776
[TBL] [Abstract][Full Text] [Related]
9. LncRNA H19 confers chemoresistance in ERα-positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK.
Si X; Zang R; Zhang E; Liu Y; Shi X; Zhang E; Shao L; Li A; Yang N; Han X; Pan B; Zhang Z; Sun L; Sun Y
Oncotarget; 2016 Dec; 7(49):81452-81462. PubMed ID: 27845892
[TBL] [Abstract][Full Text] [Related]
10. LMTK3 promotes tumorigenesis in bladder cancer via the ERK/MAPK pathway.
Jiang T; Lu X; Yang F; Wang M; Yang H; Xing N
FEBS Open Bio; 2020 Oct; 10(10):2107-2121. PubMed ID: 32865871
[TBL] [Abstract][Full Text] [Related]
11. AIB1:ERα transcriptional activity is selectively enhanced in aromatase inhibitor-resistant breast cancer cells.
O'Hara J; Vareslija D; McBryan J; Bane F; Tibbitts P; Byrne C; Conroy RM; Hao Y; Gaora PÓ; Hill AD; McIlroy M; Young LS
Clin Cancer Res; 2012 Jun; 18(12):3305-15. PubMed ID: 22550166
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in lncRNA
Yang H; Sun Q; Chong F; Jiang X; Wang Y; Xu K; Zou Y; Xu L; Song C
Aging (Albany NY); 2021 Nov; 13(21):24360-24378. PubMed ID: 34762068
[TBL] [Abstract][Full Text] [Related]
13. A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer.
Horibata S; Rice EJ; Zheng H; Mukai C; Chu T; Marks BA; Coonrod SA; Danko CG
PLoS One; 2018; 13(4):e0194522. PubMed ID: 29614078
[TBL] [Abstract][Full Text] [Related]
14. LMTK3 is implicated in endocrine resistance via multiple signaling pathways.
Stebbing J; Filipovic A; Lit LC; Blighe K; Grothey A; Xu Y; Miki Y; Chow LW; Coombes RC; Sasano H; Shaw JA; Giamas G
Oncogene; 2013 Jul; 32(28):3371-80. PubMed ID: 22869149
[TBL] [Abstract][Full Text] [Related]
15. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
16. 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion.
Wang G; Qin S; Zayas J; Ingle JN; Liu M; Weinshilboum RM; Shen K; Wang L
Breast Cancer Res Treat; 2019 Jun; 175(3):567-578. PubMed ID: 30937657
[TBL] [Abstract][Full Text] [Related]
17. Protein kinase A exhibits selective modulation of estradiol-dependent transcription in breast cancer cells that is associated with decreased ligand binding, altered estrogen receptor alpha promoter interaction, and changes in receptor phosphorylation.
Al-Dhaheri MH; Rowan BG
Mol Endocrinol; 2007 Feb; 21(2):439-56. PubMed ID: 17068199
[TBL] [Abstract][Full Text] [Related]
18. Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER
Formisano L; Stauffer KM; Young CD; Bhola NE; Guerrero-Zotano AL; Jansen VM; Estrada MM; Hutchinson KE; Giltnane JM; Schwarz LJ; Lu Y; Balko JM; Deas O; Cairo S; Judde JG; Mayer IA; Sanders M; Dugger TC; Bianco R; Stricker T; Arteaga CL
Clin Cancer Res; 2017 Oct; 23(20):6138-6150. PubMed ID: 28751448
[No Abstract] [Full Text] [Related]
19. Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
Cairns J; Ingle JN; Dudenkov TM; Kalari KR; Carlson EE; Na J; Buzdar AU; Robson ME; Ellis MJ; Goss PE; Shepherd LE; Goodnature B; Goetz MP; Weinshilboum RM; Li H; Bari MG; Wang L
JCI Insight; 2020 Aug; 5(16):. PubMed ID: 32701512
[TBL] [Abstract][Full Text] [Related]
20. Lemur tyrosine kinase-3 (LMTK3) induces chemoresistance to cetuximab in colorectal cancer via the ERK/MAPK pathway.
Wang C; Yang M; Gu X; Gu Y
Bioengineered; 2021 Dec; 12(1):6594-6605. PubMed ID: 34516351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
